Patrick Forde, Professor of Thoracic Oncology at Johns Hopkins University, shared a post on X:
”Harmoni-6 LBA now out at ESMO25.
Good numbers, PD-L1 pos & neg results are interesting. Probably going to go to the wire with ivonescimab until we see the results of the global trials incl Harmoni-3. With the good tox profile a small OS win will probably be enough!”
More from ESMO25 on OncoDaily.
You Can Also Read:
Ivonescimab Plus Chemotherapy Demonstrates Superior PFS Over Tislelizumab in Advanced Squamous NSCLC
